PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOM...

por Westin, J., Burke, J. M., Chapman, A. E., Kilavuz, T., Xu, C., Shmuely, Y., Radford, J.
Publicado 2022

PB2109: REALMIND: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA STARTING SECOND/THIRD-LINE THERAPY AND NOT RECE...

por Flowers, C. R., Burke, J. M., Vukcevic, M., Snodgrass, S., Saverno, K., Lumiqued, M. A. A.
Publicado 2022

A modeling framework for estimating children's residential exposure and dose to chlorpyrifos via dermal residue contact and nondietary ingestion.

por Zartarian, V G, Ozkaynak, H, Burke, J M, Zufall, M J, Rigas, M L, Furtaw, E J
Publicado 2000

P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY

por Gerds, A. T., Mesa, R., Burke, J. M., Grunwald, M. R., Scherber, R., Yu, J., Hamer-Maansson, J., Oh, S. T.
Publicado 2022

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LA...

por Vitolo, U., Nowakowski, G. S., Burke, J. M., Fox, C. P., Trneny, M., Chiappella, A., Waldron-Lynch, M., Hadar, N., Pachori, A., Lenz, G.
Publicado 2022

Children's exposure assessment: a review of factors influencing Children's exposure, and the data available to characterize and assess that exposure.

por Cohen Hubal, E A, Sheldon, L S, Burke, J M, McCurdy, T R, Berry, M R, Rigas, M L, Zartarian, V G, Freeman, N C
Publicado 2000

Genome‐wide association study to identify genetic loci associated with gastrointestinal nematode resistance in Katahdin sheep

por Becker, G. M., Davenport, K. M., Burke, J. M., Lewis, R. M., Miller, J. E., Morgan, J. L. M., Notter, D. R., Murdoch, B. M.
Publicado 2020

CORRIGENDUM: Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1

por Apgar, J.F., Tang, J.P., Singh, P., Balasubramanian, N., Burke, J.M., Hodges, M.R., Lasaro, M.A., Lin, L., Millard, B.L., Moore, K., Jun, L.S., Sobolov, S., Wilkins, A.K., Gao, X.
Publicado 2020

P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 ST...

por Lee, H., Flinn, I. W., Melear, J., Ramchandren, R., Friedman, J., Burke, J. M., Linhares, Y., Raval, M., Chintapatla, R., Feldman, T. A., Yimer, H., Islas-Ohlmayer, M., Dean, A., Rana, V., Gandhi, M. D., Renshaw, J., Gillespie-Twardy, A. L., Ho, L., Puhlmann, M., Guo, W., Yasenchak, C. A.
Publicado 2022

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb tri...

por Moehler, M., Heo, J., Lee, H.C., Tak, W.Y., Chao, Y., Paik, S.W., Yim, H.J., Byun, K.S., Baron, A., Ungerechts, G., Jonker, D., Ruo, L., Cho, M., Kaubisch, A., Wege, H., Merle, P., Ebert, O., Habersetzer, F., Blanc, J.F., Rosmorduc, Olivier, Lencioni, R., Patt, R., Leen, A.M., Foerster, F., Homerin, M., Stojkowitz, N., Lusky, M., Limacher, J.M., Hennequi, M., Gaspar, N., McFadden, B., De Silva, N., Shen, D., Pelusio, A., Kirn, D.H., Breitbach, C.J., Burke, J.M.
Publicado 2019